Read Full Article from The Pharma Letter
US-Ireland drugmaker Shorla Oncology has received approval from the US regulator for a new multi-dose vial of Tepylute (thiotepa), a chemotherapy treatment for breast and ovarian cancers.
The formulation, designed to improve dosing efficiency and reduce preparation errors, is the first ready-to-dilute version of the drug, removing the need for reconstitution.
